Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Citius Oncology, Inc.NASDAQ: CTOR

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q2 FY2026 research & development of $1.08M fell 65.6% year over year, behind the -39.8% change in trailing-twelve-month research & development. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at -2.2% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -65.6% toward the trailing-twelve-month pace of -39.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.08M+6.0% QoQ
Last fiscal yearSep 2025
$6.42M+30.3% YoY
LTMMar 2026
$4.11M-39.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.6%——
1 year+30.3%——
3-year CAGR-2.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.42M USD
Year-over-year change
+30.3%
3-year CAGR
-2.2%

Research & Development vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 research & development of $4.11M is the lowest of the 10 companies compared; the peer median is $27.77M.
  • Its year-over-year change of -39.8% is the 9th highest of 10, against a peer median of +1.0%.
  • Research & development amounts to 73.3% of revenue for CTOR, versus a peer median of 57.0%.
CTOR Competitors Peer median
Research & Development for CTOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$312.43M +226.5%+70.8%—
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M -23.9%-30.4%1590.8%
FBRXForte Biosciences, Inc.LTM Mar 2026$65.43M +123.8%+118.4%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$37.82M -33.6%-23.5%3297.1%
SPROSpero Therapeutics, Inc.LTM Mar 2026$27.77M -70.1%-6.9%50.7%
SCLXScilex Holding CompanyLTM Mar 2026$21.46M +138.8%+31.8%63.4%
OWLTOwlet, Inc.LTM Mar 2026$15.13M +46.7%-20.4%14.1%
ACTUActuate Therapeutics IncLTM Mar 2026$9.64M -35.9%-14.4%—
LNSRLENSAR, Inc.LTM Mar 2026$5.47M +1.0%-21.9%9.5%
CTORCitius Oncology, Inc.LTM Mar 2026$4.11M -39.8%-2.2%73.3%
Peer median (excluding CTOR) $27.77M+1.0%-14.4%57.0%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.